{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T01:05:38Z","timestamp":1788570338360,"version":"build-2803163510"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,18]],"date-time":"2020-06-18T00:00:00Z","timestamp":1592438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Prion Alliance"},{"name":"CJD Foundation"},{"DOI":"10.13039\/100013114","name":"Broad Institute","doi-asserted-by":"publisher","award":["Next Gen Fund"],"award-info":[{"award-number":["Next Gen Fund"]}],"id":[{"id":"10.13039\/100013114","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","award":["GRFP 2015214731"],"award-info":[{"award-number":["GRFP 2015214731"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["F31 AI122592"],"award-info":[{"award-number":["F31 AI122592"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["R21 TR003040"],"award-info":[{"award-number":["R21 TR003040"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Prion disease is neurodegenerative disease that is typically fatal within months of first symptoms. Clinical trials in this rapidly declining symptomatic patient population have proven challenging. Individuals at high lifetime risk for genetic prion disease can be identified decades before symptom onset and provide an opportunity for early therapeutic intervention. However, randomizing pre-symptomatic carriers to a clinical endpoint is not numerically feasible. We therefore launched a cohort study in pre-symptomatic genetic prion disease mutation carriers and controls with the goal of evaluating biomarker endpoints that may enable informative trials in this population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We collected cerebrospinal fluid (CSF) and blood from pre-symptomatic individuals with prion protein gene (\n                      <jats:italic>PRNP<\/jats:italic>\n                      ) mutations (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u200927) and matched controls (\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u200916), in a cohort study at Massachusetts General Hospital. We quantified total prion protein (PrP) and real-time quaking-induced conversion (RT-QuIC) prion seeding activity in CSF and neuronal damage markers total tau (T-tau) and neurofilament light chain (NfL) in CSF and plasma. We compared these markers cross-sectionally, evaluated short-term test-retest reliability over 2\u20134\u2009months, and conducted a pilot longitudinal study over 10\u201320\u2009months.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      CSF PrP levels were stable on test-retest with a mean coefficient of variation of 7% for both over 2\u20134\u2009months in\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u200929 participants and over 10\u201320\u2009months in\n                      <jats:italic>N<\/jats:italic>\n                      \u00a0=\u200910 participants. RT-QuIC was negative in 22\/23 mutation carriers. The sole individual with positive RT-QuIC seeding activity at two study visits had steady CSF PrP levels and slightly increased tau and NfL concentrations compared with the others, though still within the normal range, and remained asymptomatic 1\u00a0year later. T-tau and NfL showed no significant differences between mutation carriers and controls in either CSF or plasma.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CSF PrP will be interpretable as a pharmacodynamic readout for PrP-lowering therapeutics in pre-symptomatic individuals and may serve as an informative surrogate biomarker in this population. In contrast, markers of prion seeding activity and neuronal damage do not reliably cross-sectionally distinguish mutation carriers from controls. Thus, as PrP-lowering therapeutics for prion disease advance, \u201csecondary prevention\u201d based on prodromal pathology may prove challenging; instead, \u201cprimary prevention\u201d trials appear to offer a tractable paradigm for trials in pre-symptomatic individuals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12916-020-01608-8","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T21:02:43Z","timestamp":1592427763000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Cerebrospinal fluid and plasma biomarkers in individuals at risk for genetic prion disease"],"prefix":"10.1186","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-2702","authenticated-orcid":false,"given":"Sonia M.","family":"Vallabh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric Vallabh","family":"Minikel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Becky C.","family":"Carlyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison J.","family":"McManus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chase D.","family":"Wennick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bolling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bianca A.","family":"Trombetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Urick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chloe K.","family":"Nobuhara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Gerber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Duddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingolf","family":"Lachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Stehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven J.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven E.","family":"Arnold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,18]]},"reference":[{"key":"1608_CR1","doi-asserted-by":"publisher","first-page":"13363","DOI":"10.1073\/pnas.95.23.13363","volume":"95","author":"SB Prusiner","year":"1998","unstructured":"Prusiner SB. Prions. PNAS. 1998;95:13363\u201383.","journal-title":"PNAS"},{"key":"1608_CR2","doi-asserted-by":"publisher","unstructured":"Raymond GJ, Zhao HT, Race B, Raymond LD, Williams K, Swayze EE, et al. Antisense oligonucleotides extend survival of prion-infected mice. JCI Insight. 2019;5. https:\/\/doi.org\/10.1172\/jci.insight.131175.","DOI":"10.1172\/jci.insight.131175"},{"key":"1608_CR3","doi-asserted-by":"publisher","unstructured":"Minikel EV, Zhao HT, Le J, O\u2019Moore J, Pitstick R, Graffam S, et al. Prion protein lowering is a disease-modifying therapy across prion strains, disease stages, and endpoints. bioRxiv. 2020. https:\/\/doi.org\/10.1101\/2020.03.27.011940.","DOI":"10.1101\/2020.03.27.011940"},{"issue":"Pt 10","key":"1608_CR4","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/brain\/awh249","volume":"127","author":"M Pocchiari","year":"2004","unstructured":"Pocchiari M, Puopolo M, Croes EA, Budka H, Gelpi E, Collins S, et al. Predictors of survival in sporadic Creutzfeldt-Jakob disease and other human transmissible spongiform encephalopathies. Brain. 2004;127(Pt 10):2348\u201359.","journal-title":"Brain"},{"key":"1608_CR5","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.1212\/WNL.0b013e3182a9f3b4","volume":"81","author":"MD Geschwind","year":"2013","unstructured":"Geschwind MD, Kuo AL, Wong KS, Haman A, Devereux G, Raudabaugh BJ, et al. Quinacrine treatment trial for sporadic Creutzfeldt-Jakob disease. Neurology. 2013;81:2015\u201323.","journal-title":"Neurology"},{"key":"1608_CR6","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1474-4422(13)70307-7","volume":"13","author":"S Ha\u00efk","year":"2014","unstructured":"Ha\u00efk S, Marcon G, Mallet A, Tettamanti M, Welaratne A, Giaccone G, et al. Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014;13:150\u20138.","journal-title":"Lancet Neurol"},{"key":"1608_CR7","doi-asserted-by":"publisher","first-page":"322ra9","DOI":"10.1126\/scitranslmed.aad5169","volume":"8","author":"EV Minikel","year":"2016","unstructured":"Minikel EV, Vallabh SM, Lek M, Estrada K, Samocha KE, Sathirapongsasuti JF, et al. Quantifying prion disease penetrance using large population control cohorts. Sci Transl Med. 2016;8:322ra9.","journal-title":"Sci Transl Med"},{"key":"1608_CR8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1038\/ejhg.2014.42","volume":"22","author":"J Owen","year":"2014","unstructured":"Owen J, Beck J, Campbell T, Adamson G, Gorham M, Thompson A, et al. Predictive testing for inherited prion disease: report of 22 years experience. Eur J Hum Genet. 2014;22:1351\u20136.","journal-title":"Eur J Hum Genet"},{"key":"1608_CR9","doi-asserted-by":"publisher","unstructured":"Minikel EV, Vallabh SM, Orseth MC, Brandel J-P, Ha\u00efk S, Laplanche J-L, et al. Age at onset in genetic prion disease and the design of preventive clinical trials. Neurology. 2019;93(2):e125\u2013e134. https:\/\/doi.org\/10.1212\/WNL.0000000000007745.","DOI":"10.1212\/WNL.0000000000007745"},{"key":"1608_CR10","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/S1474-4422(19)30403-X","volume":"19","author":"SM Vallabh","year":"2020","unstructured":"Vallabh SM, Minikel EV, Schreiber SL, Lander ES. Towards a treatment for genetic prion disease: trials and biomarkers. Lancet Neurol. 2020;19:361\u20138.","journal-title":"Lancet Neurol"},{"key":"1608_CR11","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.neuron.2014.10.038","volume":"84","author":"R Sperling","year":"2014","unstructured":"Sperling R, Mormino E, Johnson K. The evolution of preclinical Alzheimer\u2019s disease: implications for prevention trials. Neuron. 2014;84:608\u201322.","journal-title":"Neuron"},{"key":"1608_CR12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1056\/NEJMoa1202753","volume":"367","author":"RJ Bateman","year":"2012","unstructured":"Bateman RJ, Xiong C, Benzinger TLS, Fagan AM, Goate A, Fox NC, et al. Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease. N Engl J Med. 2012;367:795\u2013804.","journal-title":"N Engl J Med"},{"key":"1608_CR13","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nrneurol.2014.24","volume":"10","author":"CA Ross","year":"2014","unstructured":"Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, et al. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10:204\u201316.","journal-title":"Nat Rev Neurol"},{"issue":"Pt 3","key":"1608_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1093\/brain\/awl003","volume":"129","author":"P Cortelli","year":"2006","unstructured":"Cortelli P, Perani D, Montagna P, Gallassi R, Tinuper P, Provini F, et al. Pre-symptomatic diagnosis in fatal familial insomnia: serial neurophysiological and 18FDG-PET studies. Brain. 2006;129(Pt 3):668\u201375.","journal-title":"Brain"},{"key":"1608_CR15","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1007\/s00415-014-7615-1","volume":"262","author":"OS Cohen","year":"2015","unstructured":"Cohen OS, Chapman J, Korczyn AD, Nitsan Z, Appel S, Hoffmann C, et al. Familial Creutzfeldt-Jakob disease with the E200K mutation: longitudinal neuroimaging from asymptomatic to symptomatic CJD. J Neurol. 2015;262:604\u201313.","journal-title":"J Neurol"},{"key":"1608_CR16","doi-asserted-by":"publisher","unstructured":"Rudge P, Jaunmuktane Z, Hyare H, Ellis M, Koltzenburg M, Collinge J, et al. Early neurophysiological biomarkers and spinal cord pathology in inherited prion disease. Brain. 2019;142(3):760\u201370. https:\/\/doi.org\/10.1093\/brain\/awy358.","DOI":"10.1093\/brain\/awy358"},{"key":"1608_CR17","doi-asserted-by":"publisher","first-page":"38737","DOI":"10.1038\/srep38737","volume":"6","author":"P Steinacker","year":"2016","unstructured":"Steinacker P, Blennow K, Halbgebauer S, Shi S, Ruf V, Oeckl P, et al. Neurofilaments in blood and CSF for diagnosis and prediction of onset in Creutzfeldt-Jakob disease. Sci Rep. 2016;6:38737.","journal-title":"Sci Rep"},{"key":"1608_CR18","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13195-019-0562-4","volume":"12","author":"S Abu-Rumeileh","year":"2019","unstructured":"Abu-Rumeileh S, Steinacker P, Polischi B, Mammana A, Bartoletti-Stella A, Oeckl P, et al. CSF biomarkers of neuroinflammation in distinct forms and subtypes of neurodegenerative dementia. Alzheimers Res Ther. 2019;12:2.","journal-title":"Alzheimers Res Ther"},{"key":"1608_CR19","doi-asserted-by":"publisher","first-page":"e127","DOI":"10.1111\/ene.13807","volume":"25","author":"G Novi","year":"2018","unstructured":"Novi G, Canosa A, Nobili F, Bongianni M, Zanusso G, Balestrino M, et al. Longitudinal brain magnetic resonance imaging and real-time quaking induced conversion analysis in presymptomatic Creutzfeldt-Jakob disease. Eur J Neurol. 2018;25:e127\u20138.","journal-title":"Eur J Neurol"},{"key":"1608_CR20","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1111\/ene.13389","volume":"24","author":"GG Kovacs","year":"2017","unstructured":"Kovacs GG, Andreasson U, Liman V, Regelsberger G, Lutz MI, Danics K, et al. Plasma and cerebrospinal fluid tau and neurofilament concentrations in rapidly progressive neurological syndromes: a neuropathology-based cohort. Eur J Neurol. 2017;24:1326\u2013e77.","journal-title":"Eur J Neurol"},{"key":"1608_CR21","doi-asserted-by":"crossref","unstructured":"Abu Rumeileh S, Lattanzio F, Stanzani Maserati M, Rizzi R, Capellari S, Parchi P. Diagnostic accuracy of a combined analysis of cerebrospinal fluid t-PrP, t-tau, p-tau, and A\u03b242 in the differential diagnosis of Creutzfeldt-Jakob disease from Alzheimer\u2019s disease with emphasis on atypical disease variants. J Alzheimers Dis. 2017;55:1471\u201380.","DOI":"10.3233\/JAD-160740"},{"key":"1608_CR22","doi-asserted-by":"publisher","unstructured":"Thompson AGB, Luk C, Heslegrave AJ, Zetterberg H, Mead SH, Collinge J, et al. Neurofilament light chain and tau concentrations are markedly increased in the serum of patients with sporadic Creutzfeldt-Jakob disease, and tau correlates with rate of disease progression. J Neurol Neurosurg Psychiatry. 2018;89(9):955\u201361. https:\/\/doi.org\/10.1136\/jnnp-2017-317793.","DOI":"10.1136\/jnnp-2017-317793"},{"key":"1608_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jamaneurol.2019.1071","volume":"76","author":"AM Staffaroni","year":"2019","unstructured":"Staffaroni AM, Kramer AO, Casey M, Kang H, Rojas JC, Orr\u00fa CD, et al. Association of blood and cerebrospinal fluid tau level and other biomarkers with survival time in sporadic Creutzfeldt-Jakob disease. JAMA Neurol. 2019;76:969\u201377.","journal-title":"JAMA Neurol"},{"key":"1608_CR24","doi-asserted-by":"publisher","unstructured":"Orr\u00fa CD, Groveman BR, Hughson AG, Zanusso G, Coulthart MB, Caughey B. Rapid and sensitive RT-QuIC detection of human Creutzfeldt-Jakob disease using cerebrospinal fluid. MBio. 2015;6(1). https:\/\/doi.org\/10.1128\/mBio.02451-14.","DOI":"10.1128\/mBio.02451-14"},{"key":"1608_CR25","doi-asserted-by":"publisher","first-page":"7793","DOI":"10.1073\/pnas.1901947116","volume":"116","author":"SM Vallabh","year":"2019","unstructured":"Vallabh SM, Nobuhara CK, Llorens F, Zerr I, Parchi P, Capellari S, et al. Prion protein quantification in human cerebrospinal fluid as a tool for prion disease drug development. PNAS. 2019;116:7793\u20138.","journal-title":"PNAS"},{"key":"1608_CR26","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208.","journal-title":"J Biomed Inform"},{"key":"1608_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1111\/j.1532-5415.2005.53221.x","volume":"53","author":"ZS Nasreddine","year":"2005","unstructured":"Nasreddine ZS, Phillips NA, B\u00e9dirian V, Charbonneau S, Whitehead V, Collin I, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"1608_CR28","doi-asserted-by":"crossref","unstructured":"Homack S, Lee D, Riccio CA. Test review: Delis-Kaplan executive function system. J Clin Exp Neuropsychol. 2005;27(5):599\u2013609.","DOI":"10.1080\/13803390490918444"},{"key":"1608_CR29","unstructured":"Strauss E, Sherman EMS, Spreen O. A compendium of neuropsychological tests: administration, norms and commentary. 3rd ed. Oxford: Oxford University Press; 2006."},{"key":"1608_CR30","volume-title":"Halstead-Reitan neuropsychological battery","author":"RM Reitan","year":"1993","unstructured":"Reitan RM, Wolfson D. Halstead-Reitan neuropsychological battery. Tucson: Neuropsychology Press; 1993."},{"key":"1608_CR31","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/s10994-015-5529-5","volume":"102","author":"W Souillard-Mandar","year":"2016","unstructured":"Souillard-Mandar W, Davis R, Rudin C, Au R, Libon DJ, Swenson R, et al. Learning classification models of cognitive conditions from subtle behaviors in the digital clock drawing test. Mach Learn. 2016;102:393\u2013441.","journal-title":"Mach Learn"},{"issue":"11 Suppl 3","key":"1608_CR32","doi-asserted-by":"publisher","first-page":"S54","DOI":"10.1212\/WNL.0b013e3182872ded","volume":"80","author":"S Weintraub","year":"2013","unstructured":"Weintraub S, Dikmen SS, Heaton RK, Tulsky DS, Zelazo PD, Bauer PJ, et al. Cognition assessment using the NIH Toolbox. Neurology. 2013;80(11 Suppl 3):S54\u201364.","journal-title":"Neurology"},{"key":"1608_CR33","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.janxdis.2005.05.004","volume":"20","author":"OT Leyfer","year":"2006","unstructured":"Leyfer OT, Ruberg JL, Woodruff-Borden J. Examination of the utility of the Beck Anxiety Inventory and its factors as a screener for anxiety disorders. J Anxiety Disord. 2006;20:444\u201358.","journal-title":"J Anxiety Disord"},{"key":"1608_CR34","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1207\/s15327752jpa6703_13","volume":"67","author":"AT Beck","year":"1996","unstructured":"Beck AT, Steer RA, Ball R, Ranieri WF. Comparison of Beck depression inventories-IA and-II in psychiatric outpatients. J Pers Assess. 1996;67:588\u201397.","journal-title":"J Pers Assess"},{"key":"1608_CR35","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1037\/0894-4105.22.4.531","volume":"22","author":"ST Farias","year":"2008","unstructured":"Farias ST, Mungas D, Reed BR, Cahn-Weiner D, Jagust W, Baynes K, et al. The Measurement of Everyday Cognition (ECog): scale development and psychometric properties. Neuropsychology. 2008;22:531\u201344.","journal-title":"Neuropsychology"},{"key":"1608_CR36","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.jalz.2011.02.007","volume":"7","author":"ST Farias","year":"2011","unstructured":"Farias ST, Mungas D, Harvey DJ, Simmons A, Reed BR, DeCarli C. The Measurement of Everyday Cognition (ECog): development and validation of a short form. Alzheimers Dement. 2011;7:593\u2013601.","journal-title":"Alzheimers Dement"},{"key":"1608_CR37","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","volume":"14","author":"MW Johns","year":"1991","unstructured":"Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14:540\u20135.","journal-title":"Sleep"},{"issue":"Pt 4","key":"1608_CR38","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1093\/brain\/awt048","volume":"136","author":"AGB Thompson","year":"2013","unstructured":"Thompson AGB, Lowe J, Fox Z, Lukic A, Porter M-C, Ford L, et al. The Medical Research Council prion disease rating scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. Brain. 2013;136(Pt 4):1116\u201327.","journal-title":"Brain"},{"key":"1608_CR39","doi-asserted-by":"crossref","unstructured":"Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the unified Parkinson\u2019s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23:2129\u201370.","DOI":"10.1002\/mds.22340"},{"key":"1608_CR40","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1212\/WNL.44.12.2308","volume":"44","author":"JL Cummings","year":"1994","unstructured":"Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44:2308\u201314.","journal-title":"Neurology"},{"key":"1608_CR41","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1212\/WNL.49.1.133","volume":"49","author":"S Capellari","year":"1997","unstructured":"Capellari S, Vital C, Parchi P, Petersen RB, Ferrer X, Jarnier D, et al. Familial prion disease with a novel 144-bp insertion in the prion protein gene in a Basque family. Neurology. 1997;49:133\u201341.","journal-title":"Neurology"},{"key":"1608_CR42","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1001\/jamaneurol.2014.4068","volume":"72","author":"A Dorey","year":"2015","unstructured":"Dorey A, Tholance Y, Vighetto A, et al. Association of cerebrospinal fluid prion protein levels and the distinction between Alzheimer disease and Creutzfeldt-Jakob disease. JAMA Neurol. 2015;72:267\u201375.","journal-title":"JAMA Neurol"},{"key":"1608_CR43","doi-asserted-by":"publisher","unstructured":"Gaetani L, H\u00f6glund K, Parnetti L, Pujol-Calderon F, Becker B, Eusebi P, et al. A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation. Alzheimers Res Ther. 2018;10. https:\/\/doi.org\/10.1186\/s13195-018-0339-1.","DOI":"10.1186\/s13195-018-0339-1"},{"key":"1608_CR44","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gissl\u00e9n","year":"2015","unstructured":"Gissl\u00e9n M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2015;3:135\u201340.","journal-title":"EBioMedicine"},{"key":"1608_CR45","first-page":"185","volume":"2017","author":"CD Orr\u00f9","year":"1658","unstructured":"Orr\u00f9 CD, Groveman BR, Hughson AG, Manca M, Raymond LD, Raymond GJ, et al. RT-QuIC assays for prion disease detection and diagnostics. Methods Mol Biol. 1658;2017:185\u2013203.","journal-title":"Methods Mol Biol"},{"key":"1608_CR46","doi-asserted-by":"publisher","unstructured":"Orr\u00fa CD, Groveman BR, Raymond LD, Hughson AG, Nonno R, Zou W, et al. Bank vole prion protein as an apparently universal substrate for RT-QuIC-based detection and discrimination of prion strains. PLoS Pathog. 2015;11(6):e1004983. https:\/\/doi.org\/10.1371\/journal.ppat.1004983.","DOI":"10.1371\/journal.ppat.1004983"},{"key":"1608_CR47","doi-asserted-by":"publisher","unstructured":"Minikel EV, Kuhn E, Cocco AR, Vallabh SM, Hartigan CR, Reidenbach AG, et al. Domain-specific quantification of prion protein in cerebrospinal fluid by targeted mass spectrometry. Mol Cell Proteomics. 2019;18(12):2388\u2013400. https:\/\/doi.org\/10.1074\/mcp.RA119.001702.","DOI":"10.1074\/mcp.RA119.001702"},{"key":"1608_CR48","doi-asserted-by":"crossref","unstructured":"Villar-Piqu\u00e9 A, Schmitz M, Lachmann I, Karch A, Calero O, Stehmann C, et al. Cerebrospinal fluid total prion protein in the spectrum of prion diseases. Mol Neurobiol. 2018.","DOI":"10.1007\/s12035-018-1251-1"},{"key":"1608_CR49","doi-asserted-by":"publisher","unstructured":"Trombetta BA, Carlyle BC, Koenig AM, Shaw LM, Trojanowski JQ, Wolk DA, et al. The technical reliability and biotemporal stability of cerebrospinal fluid biomarkers for profiling multiple pathophysiologies in Alzheimer\u2019s disease. PLoS One. 2018;13. https:\/\/doi.org\/10.1371\/journal.pone.0193707.","DOI":"10.1371\/journal.pone.0193707"},{"key":"1608_CR50","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1111\/j.1750-3639.1998.tb00176.x","volume":"8","author":"P Parchi","year":"1998","unstructured":"Parchi P, Petersen RB, Chen SG, Autilio-Gambetti L, Capellari S, Monari L, et al. Molecular pathology of fatal familial insomnia. Brain Pathol. 1998;8:539\u201348.","journal-title":"Brain Pathol"},{"key":"1608_CR51","doi-asserted-by":"publisher","first-page":"12661","DOI":"10.1074\/jbc.271.21.12661","volume":"271","author":"RB Petersen","year":"1996","unstructured":"Petersen RB, Parchi P, Richardson SL, Urig CB, Gambetti P. Effect of the D178N mutation and the codon 129 polymorphism on the metabolism of the prion protein. J Biol Chem. 1996;271:12661\u20138.","journal-title":"J Biol Chem"},{"key":"1608_CR52","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.neuron.2009.07.026","volume":"63","author":"WS Jackson","year":"2009","unstructured":"Jackson WS, Borkowski AW, Faas H, Steele AD, King OD, Watson N, et al. Spontaneous generation of prion infectivity in fatal familial insomnia knockin mice. Neuron. 2009;63:438\u201350.","journal-title":"Neuron"},{"key":"1608_CR53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s00401-016-1585-6","volume":"132","author":"JC Watts","year":"2016","unstructured":"Watts JC, Giles K, Bourkas MEC, Patel S, Oehler A, Gavidia M, et al. Towards authentic transgenic mouse models of heritable PrP prion diseases. Acta Neuropathol. 2016;132:593\u2013610.","journal-title":"Acta Neuropathol"},{"key":"1608_CR54","doi-asserted-by":"publisher","unstructured":"Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, Wild EJ, Saft C, Barker RA, et al. Targeting huntingtin expression in patients with Huntington\u2019s disease. N Engl J Med. 2019. https:\/\/doi.org\/10.1056\/NEJMoa1900907.","DOI":"10.1056\/NEJMoa1900907"},{"key":"1608_CR55","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1128\/JCM.06099-11","volume":"50","author":"CD Orr\u00f9","year":"2012","unstructured":"Orr\u00f9 CD, Hughson AG, Race B, Raymond GJ, Caughey B. Time course of prion seeding activity in cerebrospinal fluid of scrapie-infected hamsters after intratongue and intracerebral inoculations. J Clin Microbiol. 2012;50:1464\u20136.","journal-title":"J Clin Microbiol"},{"key":"1608_CR56","doi-asserted-by":"publisher","first-page":"15002","DOI":"10.1073\/pnas.0907339106","volume":"106","author":"G Tamg\u00fcney","year":"2009","unstructured":"Tamg\u00fcney G, Francis KP, Giles K, Lemus A, DeArmond SJ, Prusiner SB. Measuring prions by bioluminescence imaging. Proc Natl Acad Sci U S A. 2009;106:15002\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1608_CR57","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/msb.2009.10","volume":"5","author":"D Hwang","year":"2009","unstructured":"Hwang D, Lee IY, Yoo H, Gehlenborg N, Cho J-H, Petritis B, et al. A systems approach to prion disease. Mol Syst Biol. 2009;5:252.","journal-title":"Mol Syst Biol"},{"key":"1608_CR58","volume-title":"Neurofilament light chain (NfL) as a possible biomarker for drug efficacy in mouse models of neurodegenerative diseases","author":"M Hirouchi","year":"2019","unstructured":"Hirouchi M. Neurofilament light chain (NfL) as a possible biomarker for drug efficacy in mouse models of neurodegenerative diseases. 2019. https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6738495\/. Accessed 28 Oct 2019."},{"key":"1608_CR59","doi-asserted-by":"publisher","first-page":"8586","DOI":"10.1007\/s12035-018-1014-z","volume":"55","author":"F Llorens","year":"2018","unstructured":"Llorens F, Barrio T, Correia \u00c2, Villar-Piqu\u00e9 A, Th\u00fcne K, Lange P, et al. Cerebrospinal fluid prion disease biomarkers in pre-clinical and clinical naturally occurring scrapie. Mol Neurobiol. 2018;55:8586\u201391.","journal-title":"Mol Neurobiol"},{"key":"1608_CR60","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1136\/jnnp.2008.155242","volume":"82","author":"K Satoh","year":"2011","unstructured":"Satoh K, Nakaoke R, Nishiura Y, Tsujino A, Motomura M, Yoshimura T, et al. Early detection of sporadic CJD by diffusion-weighted MRI before the onset of symptoms. J Neurol Neurosurg Psychiatry. 2011;82:942\u20133.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1608_CR61","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s00415-016-8022-6","volume":"263","author":"F Verde","year":"2016","unstructured":"Verde F, Ticozzi N, Messina S, Calcagno N, Girotti F, Maderna L, et al. MRI abnormalities found 1 year prior to symptom onset in a case of Creutzfeldt-Jakob disease. J Neurol. 2016;263:597\u20139.","journal-title":"J Neurol"},{"key":"1608_CR62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jns.2012.04.004","volume":"319","author":"Y Terasawa","year":"2012","unstructured":"Terasawa Y, Fujita K, Izumi Y, Kaji R. Early detection of familial Creutzfeldt-Jakob disease on diffusion-weighted imaging before symptom onset. J Neurol Sci. 2012;319:130\u20132.","journal-title":"J Neurol Sci"},{"key":"1608_CR63","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/ana.24757","volume":"80","author":"G Zanusso","year":"2016","unstructured":"Zanusso G, Camporese G, Ferrari S, Santelli L, Bongianni M, Fiorini M, et al. Long-term preclinical magnetic resonance imaging alterations in sporadic Creutzfeldt-Jakob disease. Ann Neurol. 2016;80:629\u201332.","journal-title":"Ann Neurol"},{"key":"1608_CR64","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1212\/WNL.0b013e3182477eed","volume":"78","author":"N Mattsson","year":"2012","unstructured":"Mattsson N, Ros\u00e9n E, Hansson O, Andreasen N, Parnetti L, Jonsson M, et al. Age and diagnostic performance of Alzheimer disease CSF biomarkers. Neurology. 2012;78:468\u201376.","journal-title":"Neurology."},{"key":"1608_CR65","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K. Alzheimer\u2019s Disease Neuroimaging Initiative. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 2017;74:557\u201366.","journal-title":"JAMA Neurol"},{"key":"1608_CR66","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1093\/clinchem\/47.10.1776","volume":"47","author":"M Sj\u00f6gren","year":"2001","unstructured":"Sj\u00f6gren M, Vanderstichele H, Agren H, Zachrisson O, Edsbagge M, Wikkels\u00f8 C, et al. Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem. 2001;47:1776\u201381.","journal-title":"Clin Chem"},{"key":"1608_CR67","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13195-017-0331-1","volume":"10","author":"S Abu-Rumeileh","year":"2018","unstructured":"Abu-Rumeileh S, Capellari S, Stanzani-Maserati M, Polischi B, Martinelli P, Caroppo P, et al. The CSF neurofilament light signature in rapidly progressive neurodegenerative dementias. Alzheimers Res Ther. 2018;10:3.","journal-title":"Alzheimers Res Ther"},{"key":"1608_CR68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0054915","volume":"8","author":"K Sano","year":"2013","unstructured":"Sano K, Satoh K, Atarashi R, Takashima H, Iwasaki Y, Yoshida M, et al. Early detection of abnormal prion protein in genetic human prion diseases now possible using real-time QUIC assay. PLoS One. 2013;8:e54915.","journal-title":"PLoS One"},{"key":"1608_CR69","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1136\/jnnp-2018-320155","volume":"90","author":"K Blennow","year":"2019","unstructured":"Blennow K, Diaz-Lucena D, Zetterberg H, Villar-Pique A, Karch A, Vidal E, et al. CSF neurogranin as a neuronal damage marker in CJD: a comparative study with AD. J Neurol Neurosurg Psychiatry. 2019;90:846\u201353.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1608_CR70","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13195-020-00588-4","volume":"12","author":"M Colom-Cadena","year":"2020","unstructured":"Colom-Cadena M, Spires-Jones T, Zetterberg H, Blennow K, Caggiano A, DeKosky ST, et al. The clinical promise of biomarkers of synapse damage or loss in Alzheimer\u2019s disease. Alz Res Therapy. 2020;12:21.","journal-title":"Alz Res Therapy"},{"key":"1608_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/ajmg.b.32505","volume":"174","author":"LT Takada","year":"2017","unstructured":"Takada LT, Kim M-O, Cleveland RW, Wong K, Forner SA, Gala II, et al. Genetic prion disease: experience of a rapidly progressive dementia center in the United States and a review of the literature. Am J Med Genet B Neuropsychiatr Genet. 2017;174:36\u201369.","journal-title":"Am J Med Genet B Neuropsychiatr Genet"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01608-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-020-01608-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-020-01608-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T19:16:32Z","timestamp":1623957392000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-020-01608-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,18]]},"references-count":71,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1608"],"URL":"https:\/\/doi.org\/10.1186\/s12916-020-01608-8","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2019.12.13.19014217","asserted-by":"object"}]},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,18]]},"assertion":[{"value":"10 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Partners Institutional Review Board (#2017P000214). Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SEA has received honoraria and\/or travel expenses for lectures from Abbvie, Biogen, EIP Pharma, Roche, and Sironax; has received fees for consulting and\/or advisory boards from Athira, Biogen, Cassava, Cognito, Cortexyme, Sironax, and vTv; and has received grant support from Abbvie, Amylyx, EIP Pharma, and Merck. SMV has received speaking fees from Illumina and has received research support in the form of unrestricted charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals. EVM has received research support in the form of unrestricted charitable contributions from Charles River Laboratories and Ionis Pharmaceuticals and has consulted for Deerfield Management and Guidepoint. KB holds the Torsten S\u00f6derberg Professorship; has served as a consultant or on advisory boards for Abcam, Axon, Biogen, Lilly, MagQu, Novartis and Roche Diagnostics; and is a cofounder of Brain Biomarker Solutions in Gothenburg AB, a GU Ventures-based platform company at the University of Gothenburg. HZ is a Wallenberg Academy Fellow, a cofounder of Brain Biomarker Solutions in Gothenburg A.B., and a GU Ventures-based platform company at the University of Gothenburg and has served on advisory boards for Roche Diagnostics, Wave, Samumed, and CogRx.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"140"}}